Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients
Key facts
- Who runs it
- Alexandria University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 30 Jul 2026
- Expected to end
- Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- magnesium sulfate
- standard care treatment
- Record updated
- 6 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Male and female adult patients (aged ≥18 years) diagnosed with septic shock
- Resistant septic shock that requires corticosteroids
Who cannot take part
- Baseline hypermagnesemia (serum magnesium level > 2.3 mg/dL)
- Renal impairment with creatinine clearance (CrCl) < 10 ml/min
- Pregnancy
- Mixed shock
This trial is currently available in Egypt.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to assess the effect of targeting upper normal serum magnesium levels on norepinephrine requirements in adult patients with septic shock.
Read full original descriptionShow less
The main questions it aims to answer are:
1. Does maintaining upper normal serum magnesium levels lower the total cumulative dose and duration of norepinephrine therapy? 2. Does this approach reduce the intensive care unit (ICU) length of stay, duration of mechanical ventilation and mortality?
This study will compare an intervention group to a control group to see the effect of targeting upper normal serum magnesium levels.
Participants will:
* Have their serum magnesium levels assessed at baseline (Day 0), at three-day intervals (Days 3, 6, 9) thereafter and on the day of norepinephrine discontinuation. * Receive individualized intravenous magnesium sulfate infusions to achieve and maintain the target serum magnesium levels. * Have their demographic data collected and be monitored closely for clinical data, vital signs, Mean Arterial Pressure (MAP), urine output and laboratory parameters.
The 2 groups in the trial
- Intervention groupTreatment being tested
Patients will receive intravenous magnesium sulfate infusion to achieve and maintain upper normal serum magnesium levels (2.0 - 2.3 mg/dL).
Treatment: magnesium sulfate
- Control groupExisting treatment, for comparison
Patients will receive standard care to maintain serum magnesium levels (1.7 - 1.9 mg/dL).
Treatment: standard care treatment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients: a Randomized Controlled Trial.
- Record updated
- 6 October 2026